Drugs / MRTX1719
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07382544 | Feb 2026 → Jan 2030 expected | cancer of unknown primary site | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05245500 | Jun 2022 → Dec 2027 expected | malignant peripheral nerve sheath tumor, mesothelioma, non-small cell lung carcinoma, pancreatic adenocarcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRTX1719 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05245500 ↗ |
| Action | Inhibit | “MRTX1719 is a potent PRMT5-MTA inhibitor.” NCT05245500 ↗ |
| Route | Oral | “Given by mouth” NCT07382544 ↗ |
| Target | PRMT5 | “MRTX1719 is a potent PRMT5-MTA inhibitor.” NCT05245500 ↗ |